AU9402898A - Cell death agonists - Google Patents

Cell death agonists

Info

Publication number
AU9402898A
AU9402898A AU94028/98A AU9402898A AU9402898A AU 9402898 A AU9402898 A AU 9402898A AU 94028/98 A AU94028/98 A AU 94028/98A AU 9402898 A AU9402898 A AU 9402898A AU 9402898 A AU9402898 A AU 9402898A
Authority
AU
Australia
Prior art keywords
cell death
death agonists
agonists
cell
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU94028/98A
Inventor
Stanley J Korsmeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Publication of AU9402898A publication Critical patent/AU9402898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AU94028/98A 1997-09-26 1998-09-22 Cell death agonists Abandoned AU9402898A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6013397P 1997-09-26 1997-09-26
US60060133 1997-09-26
US94603997A 1997-10-07 1997-10-07
US08946039 1997-10-07
PCT/US1998/019765 WO1999016787A1 (en) 1997-09-26 1998-09-22 Cell death agonists

Publications (1)

Publication Number Publication Date
AU9402898A true AU9402898A (en) 1999-04-23

Family

ID=26739603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU94028/98A Abandoned AU9402898A (en) 1997-09-26 1998-09-22 Cell death agonists

Country Status (2)

Country Link
AU (1) AU9402898A (en)
WO (1) WO1999016787A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221615B1 (en) 1995-05-12 2001-04-24 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis
US6165732A (en) * 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6190912B1 (en) 1998-03-31 2001-02-20 Thomas Jefferson University Blk genes and uses thereof in apoptosis
WO2001000670A1 (en) * 1999-06-25 2001-01-04 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Bh3 modified peptides
US6737511B1 (en) 1999-08-16 2004-05-18 The United States Of America As Represented By The Department Of Health And Human Services Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CA2432364A1 (en) 2000-12-22 2002-08-22 Janssen Pharmaceutica N.V. Bax-responsive genes for drug target identification in yeast and fungi
DK1611153T3 (en) * 2003-04-02 2010-10-18 Univ Texas Anti-tumor effect of mutant Bik
KR100685345B1 (en) 2004-03-27 2007-02-22 학교법인조선대학교 Cell-killing peptide
JP2007535315A (en) 2004-04-02 2007-12-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム Cancer specific promoter
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US20070065421A1 (en) * 2005-09-16 2007-03-22 Firestein Gary S Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
WO2008152405A2 (en) * 2007-06-15 2008-12-18 The Queen's University Of Belfast Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US20150133450A1 (en) 2012-06-20 2015-05-14 Eutropics Pharmaceuticals, Inc. Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
PL3013353T3 (en) 2013-06-26 2021-09-20 Xigen Inflammation Ltd. Cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of cystitis
WO2015017788A1 (en) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Method for predicting cancer sensitivity
AU2014342269B2 (en) 2013-10-30 2020-02-27 Eutropics Pharmaceuticals, Inc. Methods for determining chemosensitivity and chemotoxicity
PL222795B1 (en) * 2013-12-22 2016-09-30 Univ Warszawski Rekombinant fusion protein ProSTAT and its application
CN104193826B (en) * 2014-09-17 2018-02-23 山东大学齐鲁医院 A kind of fused polypeptide and its application in antineoplastic is prepared
US10793915B2 (en) 2015-01-12 2020-10-06 Eutropics Pharmaceuticals, Inc. Context dependent diagnostics test for guiding cancer treatment
CA2982928A1 (en) 2015-04-20 2016-10-27 Tolero Pharmaceuticals, Inc. Predicting response to alvocidib by mitochondrial profiling
EP4086264B1 (en) 2015-05-18 2023-10-25 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
AU2016301315C1 (en) 2015-08-03 2022-07-07 Sumitomo Pharma Oncology, Inc. Combination therapies for treatment of cancer
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
AU2017379847B2 (en) 2016-12-19 2022-05-26 Sumitomo Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
MX2021006544A (en) 2018-12-04 2021-07-07 Sumitomo Pharma Oncology Inc Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer.
JP2022525149A (en) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
CN113549143B (en) * 2021-07-21 2022-05-27 吉林大学 Anti-tumor polypeptide Bax-BH3, fluorescent polymer nano micelle and preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652122A (en) * 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
US5656725A (en) * 1995-05-12 1997-08-12 Apoptosis Technology, Inc. Peptides and compositions which modulate apoptosis

Also Published As

Publication number Publication date
WO1999016787A9 (en) 1999-06-24
WO1999016787A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
AU9402898A (en) Cell death agonists
EP0882553B8 (en) Knife
AU5998598A (en) Electrochemical cell
AU1268899A (en) Microstrip arrangement
AU1407699A (en) Distributed architecture utility
AU1709299A (en) Mixer-injectors
AU5566598A (en) Hydrogels
AU1725099A (en) Devices for cloaking transplanted cells
AU2548699A (en) Cell death inhibitors
AU7349298A (en) Prostaglandin agonists
AU1027499A (en) 32P-polyphosphazene
AU6345498A (en) Antisense compounds which prevent cell death and uses thereof
AU5185899A (en) Pack
AU8180298A (en) Utility knife
AU8979698A (en) Solutions containing azasteroids
AU6036099A (en) Battery holder
AU4117497A (en) Micropolarimeter
AU9732098A (en) Hematopoietic stem cells
AU5185799A (en) Pack
AU8243798A (en) Agm-derived stroma cells
AU6634298A (en) Biosensor for cells
AU1505999A (en) Immunosuppressant agonists
AU1913299A (en) Battery cathode
AU9649198A (en) Enclosed cell
AU4469997A (en) Heregulin-gamma

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase